With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma||Duke University Medical Center / Gerard Blobe, MD, PhD||Reach Grants||2013||North Carolina|
|Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition||Children's Hospital of Philadelphia / Yael Mossé, MD||Reach Grants||2013||Pennsylvania|
|Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma||Beckman Research Institute of City of Hope / Margarita Gutova, MD||Reach Grants||2013||California|
|Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL||University of Colorado Denver / Doug Graham, MD, PhD||Reach Grants||2013||Colorado|
|Epigenomics of High Risk Pediatric T Cell Leukemia||New York University School of Medicine / Iannis Aifantis, PhD||Reach Grants||2013||New York|
|Moving EphB4 Therapeutics to Pediatric Phase I/II Trials||Oregon Health & Science University / Charles Keller, MD||Reach Grants||2013||Oregon|
|Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma||Massachusetts General Hospital / Rakesh Jain, PhD||Reach Grants||2013||Massachusetts|
|DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Reach Grants||2016||Pennsylvania|
|Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor||Northwestern University (Illinois) / Rintaro Hashizume, MD/PhD||Reach Grants||2018||Illinois|
|Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias||National Cancer Institute / Andre Nussenzweig, Ph.D.||Reach Grants||2014||Maryland|